We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Interplay between Klebsiella pneumoniae producing KPC-31 and KPC-3 under treatment with high dosage meropenem: a case report.
- Authors
Arcari, Gabriele; Oliva, Alessandra; Sacco, Federica; Di Lella, Federica Maria; Raponi, Giammarco; Tomolillo, Dario; Curtolo, Ambrogio; Venditti, Mario; Carattoli, Alessandra
- Abstract
The objective was to study ceftazidime-avibactam resistant and susceptible Klebsiella pneumoniae isolated from a patient admitted to the Policlinico Umberto I of Rome for SARS-CoV2. Data on the evolution of patient's conditions, antimicrobial therapies, and microbiological data were collected. Whole-genome sequencing performed by Illumina and Nanopore sequencing methods were used to type the strains. During the hospitalization, a SARS-CoV2-infected patient was colonized by a KPC-producing K. pneumoniae strain and empirically treated with ceftazidime-avibactam (CZA) when presenting spiking fever symptoms. Successively, ST2502 CZA-resistant strain producing the KPC-31 variant gave a pulmonary infection to the patient. The infection was treated with high doses of meropenem. The KPC-31-producing strain disappeared but the patient remained colonized by a KPC-3-producing K. pneumoniae strain. An interplay between highly conserved KPC-31- and KPC-3-producing ST2502 strains occurred in the SARS-CoV2 patient during the hospitalization, selected by CZA and carbapenem treatments, respectively.
- Subjects
KLEBSIELLA pneumoniae; MEROPENEM; NUCLEOTIDE sequencing; DRUG dosage; SARS-CoV-2; LUNG infections
- Publication
European Journal of Clinical Microbiology & Infectious Diseases, 2022, Vol 41, Issue 3, p495
- ISSN
0934-9723
- Publication type
Article
- DOI
10.1007/s10096-021-04388-y